Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927677 · ClinicalTrials.gov registry record · Phase 1
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
A Phase 1 study of Gout and Hyperuricemia, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03927677 is a Phase 1 study of Gout and Hyperuricemia that has completed, run by LG Chem. The registered enrollment target is 24 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03927677, a Phase 1 study of Gout and Hyperuricemia, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.
Conditions Studied
Interventions
- DRUG Xanthine Oxidase Inhibitor
Study Locations (1)
Texas
- PPD - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-11-05 |
| Est. Completion | 2019-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927677
The ClinicalTrials.gov registry entry for NCT03927677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gout appearing as the primary indexed condition, and to 1 intervention - of which Xanthine Oxidase Inhibitor is the first listed.
NCT03927677 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03927677 about?
NCT03927677 is a clinical study titled "The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.". This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.
What is the current status of trial NCT03927677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-11-05. Estimated completion is 2019-11-26.
What conditions does trial NCT03927677 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia.
What interventions are being tested in trial NCT03927677?
The interventions under investigation include: Xanthine Oxidase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT03927677?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927677 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.